|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 4
Zeitschriftenartikel
Modest, D. P.; Fischer von Weikersthal, L.; Decker, T.; Vehling-Kaiser, U.; Uhlig, J.; Schenk, M.; Freiberg-Richter, J.; Peuser, B.; Denzlinger, C.; Reddemann, C. Peveling Genannt; Graeven, U.; Schuch, G.; Schwaner, I.; Stahler, A.; Jung, A.; Held, S.; Stintzing, S.; Giessen-Jung, C. und Heinemann, V.
(2017):
Sequential first-line therapy of metastatic colorectal cancer (mCRC) starting with fluoropyrimidine (FP) plus bevacizumab (BEV) vs. initial FP plus irinotecan (IRI) and BEV: German AIO KRK0110 (ML22011) study.
In: Annals of Oncology, Bd. 28
Modest, Dominik P.; Ricard, Ingrid; Heinemann, Volker; Hegewisch-Becker, S.; Schmiegel, W.; Porschen, R.; Stintzing, Sebastian; Graeven, U.; Arnold, D.; Fischer von Weikersthal, L.; Giessen-Jung, Clemens; Stahler, A.; Schmoll, H. J.; Jung, A.; Kirchner, T.; Tannapfel, A. und Reinacher-Schick, A.
(September 2016):
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
In: Annals of Oncology, Bd. 27, Nr. 9: S. 1746-1753
[PDF, 410kB]
Giessen, C.; Graeven, U.; Laubender, Rüdiger P.; Modest, D. P.; Schulz, C.; Porschen, R.; Schmiegel, W.; Reinacher-Schick, A.; Hegewisch-Becker, S.; Stintzing, S. und Heinemann, V.
(2013):
Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group.
In: Annals of Oncology, Bd. 24, Nr. 12: S. 3051-3055
Buske, C.; Hoster, Eva; Dreyling, Martin; Eimermacher, H.; Wandt, H.; Metzner, B.; Fuchs, R.; Bittenbring, J.; Wörmann, Bernhard; Hohloch, K.; Hess, G.; Ludwig, W. D.; Schimke, J.; Schmitz, S.; Kneba, M.; Reiser, M.; Graeven, U.; Klapper, Wolfram; Unterhalt, Michael und Hiddemann, Wolfgang
(2009):
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG).
In: Leukemia, Bd. 23, Nr. 1: S. 153-161